
Kura Oncology, Inc. – NASDAQ:KURA
Kura Oncology stock price today
Kura Oncology stock price monthly change
Kura Oncology stock price quarterly change
Kura Oncology stock price yearly change
Kura Oncology key metrics
Market Cap | 686.65M |
Enterprise value | 772.88M |
P/E | -6.07 |
EV/Sales | N/A |
EV/EBITDA | -5.81 |
Price/Sales | N/A |
Price/Book | 1.92 |
PEG ratio | 1.99 |
EPS | -2.17 |
Revenue | N/A |
EBITDA | -178.75M |
Income | -168.08M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeKura Oncology stock price history
Kura Oncology stock forecast
Kura Oncology financial statements
$19
Potential upside: 159.20%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 0 | -37.17M | |
---|---|---|---|
Sep 2023 | 0 | -38.60M | |
Dec 2023 | 1.27M | -42.78M | -3368.98% |
Mar 2024 | 0 | -49.52M |
Jun 2023 | 494737000 | 11.16M | 2.26% |
---|---|---|---|
Sep 2023 | 473771000 | 43.83M | 9.25% |
Dec 2023 | 448935000 | 51.66M | 11.51% |
Mar 2024 | 553908000 | 48.82M | 8.81% |
Jun 2023 | -25.61M | -46.32M | 94.00M |
---|---|---|---|
Sep 2023 | -29.02M | 8.55M | 84K |
Dec 2023 | -34.30M | 42.19M | 691K |
Mar 2024 | -48.84M | -95.33M | 148.36M |
Kura Oncology alternative data
Aug 2023 | 131 |
---|---|
Sep 2023 | 133 |
Oct 2023 | 133 |
Nov 2023 | 133 |
Dec 2023 | 131 |
Jan 2024 | 131 |
Feb 2024 | 131 |
Mar 2024 | 142 |
Apr 2024 | 142 |
May 2024 | 142 |
Jun 2024 | 142 |
Jul 2024 | 142 |
Kura Oncology other data
Period | Buy | Sel |
---|---|---|
Jan 2024 | 0 | 101957 |
May 2024 | 0 | 2615 |
Nov 2024 | 0 | 526 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | FORD KATHLEEN officer: Chief Op.. | Common Stock | 526 | $16.03 | $8,434 | ||
Sale | BAIR TERESA BROPHY officer: Chief Legal Officer | Common Stock | 2,615 | $22.15 | $57,917 | ||
Sale | DALE STEPHEN officer: Chief Me.. | Common Stock | 4,825 | $21.55 | $103,979 | ||
Sale | DOYLE THOMAS JAMES officer: SVP, Finance & Account.. | Common Stock | 594 | $17.8 | $10,574 | ||
Sale | DOYLE THOMAS JAMES officer: SVP, Finance & Account.. | Common Stock | 761 | $17.8 | $13,547 | ||
Sale | DOYLE THOMAS JAMES officer: SVP, Finance & Account.. | Common Stock | 963 | $17.8 | $17,142 | ||
Sale | BAIR TERESA BROPHY officer: Chief Legal Officer | Common Stock | 2,053 | $17.8 | $36,545 | ||
Sale | FORD KATHLEEN officer: Chief Op.. | Common Stock | 1,496 | $17.8 | $26,630 | ||
Sale | DALE STEPHEN officer: Chief Me.. | Common Stock | 4,400 | $17.8 | $78,324 | ||
Sale | DALE STEPHEN officer: Chief Me.. | Common Stock | 2,758 | $17.8 | $49,095 |
Patent |
---|
Application Filling date: 26 Mar 2020 Issue date: 2 Jun 2022 |
Application Filling date: 12 Mar 2020 Issue date: 12 May 2022 |
Application Filling date: 28 Feb 2020 Issue date: 12 May 2022 |
Application Filling date: 28 Sep 2021 Issue date: 21 Apr 2022 |
Application Filling date: 20 Dec 2019 Issue date: 10 Mar 2022 |
Application Filling date: 31 Oct 2019 Issue date: 6 Jan 2022 |
Grant Filling date: 13 Jun 2018 Issue date: 28 Dec 2021 |
Application Filling date: 17 Aug 2021 Issue date: 9 Dec 2021 |
Grant Filling date: 2 Nov 2017 Issue date: 21 Sep 2021 |
Application Filling date: 17 May 2019 Issue date: 12 Aug 2021 |
Quarter | Transcript |
---|---|
Q1 2024 2 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 27 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 3 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 6 Aug 2023 | Q2 2023 Earnings Call Transcript |
Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)
Kura Oncology: Riding The Menin Hype Wave In AML Therapy
Kura's Ziftomenib: The Swiss Army Knife In AML Therapy
Kura Oncology: Targeted AML Therapy Continues To Deliver
Kura Oncology: Multiple Catalysts Provide Strong Upside Potential
Syndax Pharmaceuticals: 2023 Is A Pivotal Year
Kura Oncology: Good Cash, Some Good Data, A Few Problems
Kura Oncology: Targeting NPM1 Mutations In Acute Myeloid Leukemia
Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity
-
What's the price of Kura Oncology stock today?
One share of Kura Oncology stock can currently be purchased for approximately $7.33.
-
When is Kura Oncology's next earnings date?
Unfortunately, Kura Oncology's (KURA) next earnings date is currently unknown.
-
Does Kura Oncology pay dividends?
No, Kura Oncology does not pay dividends.
-
How much money does Kura Oncology make?
Kura Oncology has a market capitalization of 686.65M.
-
What is Kura Oncology's stock symbol?
Kura Oncology, Inc. is traded on the NASDAQ under the ticker symbol "KURA".
-
What is Kura Oncology's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Kura Oncology?
Shares of Kura Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Kura Oncology's key executives?
Kura Oncology's management team includes the following people:
- Dr. Troy Edward Wilson Chairman, Chief Executive Officer & Pres(age: 56, pay: $1,110,000)
- Dr. Marc Grasso Chief Financial Officer & Chief Bus. Officer(age: 52, pay: $715,950)
- Ms. Kathleen Ford Chief Operating Officer(age: 78, pay: $683,400)
- Ms. Kirsten Flowers Chief Commercial Officer(age: 50, pay: $661,250)
- Dr. Stephen Dale M.D. Chief Medical Officer(age: 53, pay: $398,930)
-
How many employees does Kura Oncology have?
As Jul 2024, Kura Oncology employs 142 workers.
-
When Kura Oncology went public?
Kura Oncology, Inc. is publicly traded company for more then 9 years since IPO on 16 Sep 2015.
-
What is Kura Oncology's official website?
The official website for Kura Oncology is kuraoncology.com.
-
Where are Kura Oncology's headquarters?
Kura Oncology is headquartered at 12730 High Bluff Drive, San Diego, CA.
-
How can i contact Kura Oncology?
Kura Oncology's mailing address is 12730 High Bluff Drive, San Diego, CA and company can be reached via phone at 858 500 8800.
-
What is Kura Oncology stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Kura Oncology in the last 12 months, the avarage price target is $19. The average price target represents a 159.20% change from the last price of $7.33.
Kura Oncology company profile:

Kura Oncology, Inc.
kuraoncology.comNASDAQ
142
Biotechnology
Healthcare
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
San Diego, CA 92130
CIK: 0001422143
ISIN: US50127T1097
CUSIP: 50127T109